Sino Biopharmaceutical Limited

Informe acción SEHK:1177

Capitalización de mercado: HK$64.4b

Sino Biopharmaceutical Crecimiento futuro

Future controles de criterios 3/6

Sino Biopharmaceutical is forecast to grow earnings and revenue by 12.9% and 9% per annum respectively. EPS is expected to grow by 13% per annum. Return on equity is forecast to be 9.2% in 3 years.

Información clave

12.9%

Tasa de crecimiento de los beneficios

13.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals11.1%
Tasa de crecimiento de los ingresos9.0%
Rentabilidad financiera futura9.2%
Cobertura de analistas

Good

Última actualización04 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Oct 02
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sep 02
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Jul 12
Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

May 21
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Apr 21
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Apr 03
What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 20
Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Dec 18
Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Dec 02
Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

Nov 17
Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Aug 30
We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

May 26
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Apr 20
Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Feb 09
Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Nov 11
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Oct 24
Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Jul 08
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Apr 28
Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Previsiones de crecimiento de beneficios e ingresos

SEHK:1177 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/202636,3243,6615,9568,46721
12/31/202532,7283,2076,1187,73625
12/31/202429,5643,4625,2807,12025
6/30/202427,7902,1425,3456,473N/A
3/31/202426,9951,9954,9686,269N/A
12/31/202326,1991,8474,5916,066N/A
6/30/202325,1161,2543,3144,987N/A
3/31/202325,5711,6564,0175,626N/A
12/31/202226,0262,0594,7196,265N/A
9/30/202228,2415,2964,8956,622N/A
6/30/202227,7018,0495,0716,980N/A
3/31/202227,21513,655N/AN/AN/A
12/31/202126,86114,6083,4995,366N/A
9/30/202126,12912,465N/AN/AN/A
6/30/202125,35310,0114,3376,105N/A
3/31/202124,6683,809N/AN/AN/A
12/31/202023,6472,7713,5375,325N/A
9/30/202023,0392,302N/AN/AN/A
6/30/202024,3542,5581,8273,373N/A
3/31/202024,2482,781N/AN/AN/A
12/31/201924,2342,7623,6225,325N/A
9/30/201924,4799,101N/AN/AN/A
6/30/201923,6919,1254,7746,543N/A
3/31/201922,4449,132N/AN/AN/A
12/31/201820,8899,0463,4175,094N/A
9/30/201819,1032,567N/AN/AN/A
6/30/201817,0622,4361,2312,572N/A
3/31/201815,6092,363N/AN/AN/A
12/31/201714,8192,171N/A3,733N/A
9/30/201714,4912,115N/AN/AN/A
6/30/201714,2581,862N/A4,773N/A
3/31/201713,8991,789N/AN/AN/A
12/31/201613,5431,637N/A2,995N/A
9/30/201613,2711,674N/AN/AN/A
6/30/201612,8581,604N/A1,757N/A
3/31/201612,5071,575N/AN/AN/A
12/31/201512,1891,490N/A1,919N/A
9/30/201512,0301,432N/AN/AN/A
6/30/201511,1241,447N/A1,973N/A
3/31/201510,5521,263N/AN/AN/A
12/31/20149,9001,210N/A1,840N/A
9/30/20149,2051,074N/AN/AN/A
6/30/20148,876951N/A2,000N/A
3/31/20148,434886N/AN/AN/A
12/31/20137,731809N/A1,230N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: 1177's forecast earnings growth (12.9% per year) is above the savings rate (2.3%).

Beneficios vs. Mercado: 1177's earnings (12.9% per year) are forecast to grow faster than the Hong Kong market (11.5% per year).

Beneficios de alto crecimiento: 1177's earnings are forecast to grow, but not significantly.

Ingresos vs. Mercado: 1177's revenue (9% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).

Ingresos de alto crecimiento: 1177's revenue (9% per year) is forecast to grow slower than 20% per year.


Previsiones de crecimiento de los beneficios por acción


Rentabilidad financiera futura

ROE futura: 1177's Return on Equity is forecast to be low in 3 years time (9.2%).


Descubre empresas en crecimiento